Abstract Number: 0330 • ACR Convergence 2022
Assessing the Utility of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Impairment in Patients with SLE Using a Bayesian Item-Response Theory Model
Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric syndromes in patients with SLE, with a prevalence ranging from 20% to…Abstract Number: 2058 • ACR Convergence 2022
Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus
Background/Purpose: Cognitive impairment (CI) is prevalent in SLE and negatively impacts social and occupational engagement. There is a need for a patient-reported outcome measure (PROM)…Abstract Number: 0363 • ACR Convergence 2022
Centrally-Acting Angiotensin Converting Enzyme Inhibitor (cACEi) and Angiotensin Receptor Blocker (cARB) Use and Cognitive Dysfunction in Patients with Systemic Lupus
Background/Purpose: Cognitive dysfunction (CD) is detectable in 40% of patients with systemic lupus erythematosus (SLE). Despite this high prevalence, there are limited treatment options for…Abstract Number: 2074 • ACR Convergence 2022
Poor Executive Function Correlates with Increased Disease Damage and Impaired Patient-Reported Outcomes in Youth with Childhood-Onset Lupus: A Cross-Sectional Study
Background/Purpose: Cognitive dysfunction affects up to 60% of youth with childhood-onset systemic lupus erythematosus (cSLE), particularly executive dysfunction (ED), with adverse effects on treatment adherence,…Abstract Number: 0456 • ACR Convergence 2021
Functional Connectivity, Enhanced Blood-Brain Barrier Leakage and Cognitive Impairment in Systemic Lupus Erythematosus
Background/Purpose: Cognitive impairment is the most frequent manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE), yet the mechanisms underlying it remain poorly understood. We have previously…Abstract Number: 0777 • ACR Convergence 2021
Potential Biomarkers of Cognitive Impairment in the Context of Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Cognitive complaints are common in children with childhood-onset systemic lupus erythematosus (cSLE), but neuropsychiatric lupus (NPSLE) remains challenging to diagnose and treat. To increase…Abstract Number: 0859 • ACR Convergence 2021
Evaluation of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Dysfunction in Systemic Lupus Erythematosus
Background/Purpose: Cognitive dysfunction (CD) affects approximately 40% of SLE patients (1), impacting on employment, daily function, and quality of life (2)(3). Diagnostic neuropsychological testing is…Abstract Number: 0872 • ACR Convergence 2021
Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Cognitive dysfunction (CD) is reported to affect approximately 40% of SLE patients (1). Mood disorders have been associated with both cognitive symptoms and cognitive…Abstract Number: 0885 • ACR Convergence 2021
SLE Phenotypes Formed from Machine Learning and Their Associations with Cognitive Impairment
Background/Purpose: Cognitive impairment (CI) in SLE is a significant problem with limited treatment options. This is in part due to the uncertainty regarding the multifaceted…Abstract Number: 0887 • ACR Convergence 2021
Association of Mycophenolate and Azathioprine Use with Cognitive Function in SLE
Background/Purpose: Cognitive dysfunction (CD) is a common manifestation of systemic lupus erythematosus (SLE) which can have detrimental consequences for those affected. To date, no treatments…Abstract Number: 0889 • ACR Convergence 2021
Association of Subjective Cognitive Report Using PDQ-20 to a Neuropsychological Battery in a Cohort of SLE Patients
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to a number of neuropsychiatric manifestations including cognitive impairment (CI). Previous meta-analyses have reported the prevalence of CI…Abstract Number: 0892 • ACR Convergence 2021
Screening for Cognitive Impairment with the Automated Neuropsychological Assessment Metrics in Patients with Systemic Lupus Erythematosus
Background/Purpose: The American College of Rheumatology Neuropsychological Battery (ACR-NB) is the standard screening test for cognitive impairment (CI) in systemic lupus erythematosus (SLE). While the…Abstract Number: 0895 • ACR Convergence 2021
Insight into Intraindividual Variability Across Neuropsychological Tests and Its Association with Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
Background/Purpose: Dispersion is defined as the variability in an individual’s performance across multiple tasks at a single assessment visit. This measure has been studied in…Abstract Number: 1293 • ACR Convergence 2021
Studying Clusters of Patients with SLE According to Cognitive Function, Self-reported Outcomes, Disease Activity, and Clusters Dynamic over 1 Year
Background/Purpose: Systemic Lupus Erythematosus (SLE) has a high prevalence of cognitive impairment (CI) (38% (95% confidence interval: 33-43%)). Patient reported outcomes (PROs) capture patient perceptions…Abstract Number: 1317 • ACR Convergence 2021
Impairment of Memory in Axial Spondyloarthritis?
Background/Purpose: There is certain evidence that neuropsychiatric changes occur in systemic lupus(1) and rheumatoid arthritis (2). However, there is little knowledge about possible cognitive changes…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 9
- Next Page »
